Travere Therapeutics price target raised by $2 at H.C. Wainwright, here’s why

H.C. Wainwright raised the firm’s price target on Travere Therapeutics to $20 from $18 and keeps a Buy rating on the shares after the company announced it opened enrollment in the HARMONY study, a pivotal Phase 3 clinical trial of pegtibatinase for the treatment of classical homocystinuria. The analyst believes the Street undervalues the company’s pegtibatinase program. The firm continues to believe pegtibatinase has the potential to become the first disease-modifying treatment for homocystinuria.